首页> 美国卫生研究院文献>Oncotarget >Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer
【2h】

Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer

机译:功能性长春新碱加达沙替尼脂质体在三阴性乳腺癌中删除血管生成模拟通道的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Standard chemotherapy cannot eradicate triple-negative breast cancer (TNBC) while the residual cancer cells readily form the vasculogenic mimicry (VM) channels, which lead to the relapse of cancer after treatment. In this study, the functional vincristine plus dasatinib liposomes, modified by a targeting molecule DSPE-PEG2000-c(RGDyK), were fabricated to address this issue. The investigations were performed on TNBC MDA-MB-231 cells and MDA-MB-231 xenografts in nude mice. The liposomes exhibited the superior performances in the following aspects: the enhancement of cellular uptake via targeted action; the induction of apoptosis via activation of caspase 8, 9, and 3, increased expression of Bax, decreased expression of Mcl-1, and generation of reactive oxygen species (ROS); and the deletion of VM channels via inhibitions on the VM channel indicators, which consisted of vascular endothelial-cadherin (VE-Cad), focal adhesion kinase (FAK), phosphatidylinositide 3-kinase (PI3K), and matrix metallopeptidases (MMP-2, and MMP-9). Furthermore, the liposomes displayed the prolonged circulation time in the blood, the increased accumulation in tumor tissue, and the improved therapeutic efficacy along with deletion of VM channels in the TNBC-bearing mice. In conclusion, the nanostructured functional drug-loaded liposomes may provide a promising strategy for the treatment of invasive TNBC along with deletion of VM channels.
机译:标准化学疗法无法根除三阴性乳腺癌(TNBC),而残留的癌细胞很容易形成血管生成模拟(VM)通道,导致治疗后癌症复发。在这项研究中,功能性长春新碱与达沙替尼脂质体经靶向分子DSPE-PEG2000-c(RGDyK)修饰后得以制备,以解决此问题。对裸鼠中的TNBC MDA-MB-231细胞和MDA-MB-231异种移植进行了研究。脂质体在以下方面表现出优异的性能:通过靶向作用增强细胞摄取;通过激活胱天蛋白酶8、9和3,Bax表达增加,Mcl-1表达减少和活性氧(ROS)的产生诱导凋亡。并通过抑制VM通道指标来删除VM通道指标,该指标由血管内皮钙粘蛋白(VE-Cad),粘着斑激酶(FAK),磷脂酰肌醇3激酶(PI3K)和基质金属肽酶(MMP-2,和MMP-9)。此外,脂质体在携带TNBC的小鼠中显示出延长的血液循环时间,在肿瘤组织中的积累增加,以及改善的治疗功效以及VM通道的缺失。总之,纳米结构的功能性载药脂质体可能为有创TNBC的治疗以及VM通道的缺失提供了有希望的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号